{"slideshow_credits": null, "snippet": "Strategically, the $21 billion deal for Pharmacyclics seems to make sense for AbbVie, but at least some analysts said the company had paid too much.", "abstract": "Venture capitalist and Pharmacyclics chief executive Robert Duggan is selling publicly traded cancer drug company he rescued to drug maker AbbVie for $21 billion, but some analysts say company is not worth the price; AbbVie needs new popular drugs to sustain growth, however, and Pharmacyclics cancer drug Imbruvica could be just the ticket.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": "William Alden contributed reporting."}, "web_url": "http://www.nytimes.com/2015/03/06/business/abbvie-wins-bidding-war-for-maker-of-cancer-drug-then-goes-on-defensive.html", "lead_paragraph": "Strategically, the $21 billion deal for Pharmacyclics seems to make sense for AbbVie, but at least some analysts said the company had paid too much.", "headline": {"main": "AbbVie Wins Bidding War for Maker of Cancer Drug, Then Goes on Defensive", "print_headline": "AbbVie Wins Bidding War, Then Goes on Defensive"}, "_id": "54f90bd938f0d81f0d7a61ba", "word_count": "1225", "multimedia": [{"height": 126, "url": "images/2015/03/06/business/DB-DRUG1/DB-DRUG1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/03/06/business/DB-DRUG1/DB-DRUG1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/03/06/business/DB-DRUG1/DB-DRUG1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/03/06/business/DB-DRUG1/DB-DRUG1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/03/06/business/DB-DRUG1/DB-DRUG1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/03/06/business/DB-DRUG1/DB-DRUG1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-03-06T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "AbbVie Inc", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Pharmacyclics, Incorporated", "is_major": "Y", "rank": "3"}, {"name": "persons", "value": "Duggan, Robert W", "is_major": "Y", "rank": "4"}, {"name": "subject", "value": "Cancer", "is_major": "Y", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "News"}